Efficacy and safety of trastuzumab deruxtecan in patients with her2-expressing solid tumors: Primary results from the destiny-pantumor02 phase ii trial - Meric-Bernstam, F; Makker, V; Oaknin, A (J Clin Oncol, 2024)